跳至主要内容
临床试验/NCT00346320
NCT00346320已完成不适用

A Phase II Study of Accelerated Hypofractionated 3-Dimensional Conformal Radiotherapy (3DCRT) For Inoperable Stage I/II Non-Small Cell Lung Cancer (NSCLC)

NCIC Clinical Trials Group19 个研究点 分布在 1 个国家目标入组 80 人开始时间: 2006年8月2日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
80
试验地点
19
主要终点
Local tumor control rate at 2 years

研究概览

简要总结

RATIONALE: Radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue.

PURPOSE: This phase II trial is studying how well radiation therapy works in treating patients with stage I or stage II non-small cell lung cancer that cannot be removed by surgery.

详细描述

OBJECTIVES:

Primary

  • Determine the local tumor control rate at 2 years after accelerated hypofractionated 3-dimensional, conformal radiotherapy in patients with inoperable T1-3 N0 M0 non-small cell lung cancer.

Secondary

  • Determine the toxicities of this regimen in these patients.
  • Determine the rates of regional and distant disease recurrence in these patients.
  • Determine the progression-free and overall survival of patients treated with this regimen.
  • Determine the changes in pulmonary function after treatment in these patients.
  • Assess the quality of life of patients after treatment.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •DISEASE CHARACTERISTICS:
  • •Histologically or cytologically confirmed non-small cell lung cancer (NSCLC)
  • •Stage I or II peripheral disease
  • •T1, N0, M0
  • •T2 (≤ 5 cm), N0, M0
  • •T3 (≤ 5 cm, chest wall primary tumor only), N0, M0
  • •No T2-T3 primary tumors > 5 cm or any T1-T3 tumor of the mainstem bronchus involvement
  • •No T1-T3 tumor in the lung apex (i.e., tumor in a position that will result in irradiation of the brachial plexus to the prescribed dose)
  • •Hilar or mediastinal lymph nodes ≤ 1 cm considered N0
  • •Any of the following primary cancer types:
  • •Squamous cell carcinoma
  • •Adenocarcinoma
  • •Large cell carcinoma
  • •Bronchioloalveolar cell carcinoma
  • •Non-small cell carcinoma not otherwise specified
  • •Underlying physiological medical condition that prohibits surgery due to a low probability of tolerating general anesthesia, the operation, the postoperative recovery period, or the removal of adjacent functional lung (i.e., medically inoperable)
  • •Cytologic specimens obtained by brushing, washing, or needle aspiration of defined lesion allowed
  • •If sputum cytology alone is used for diagnosis, it must be confirmed on a second specimen
  • •Must develop a radiotherapy plan that meets the dose-volume constraints for critical organs
  • •No ataxia telangiectasia
  • •PATIENT CHARACTERISTICS:
  • •ECOG performance status 0-2
  • •Not pregnant or nursing
  • •Able and willing to complete a quality of life questionnaire unless not literate in either English or French (i.e., a translator is required to comprehend the questions and reply)
  • •No active systemic, pulmonary, or pericardial infection
  • •No previous malignancy except adequately treated nonmelanomatous skin cancer or carcinoma in situ of the cervix.
  • •Previous diagnosis of cancer that is free of recurrence and metastases for ≥ 2 years and, in the opinion of the treating physician, does not have a substantial risk of recurrence allowed (including prior lung cancer)
  • •PRIOR CONCURRENT THERAPY:
  • •No prior radiotherapy to the area of the primary tumor
  • •No prior or concurrent chemotherapy or immunotherapy for this tumor

排除标准

  • 未提供

研究组 & 干预措施

Radiotherapy

Experimental

3-dimensional conformal radiotherapy, 60 Gy in once daily 4 Gy fractions (Monday to Friday) over 3 weeks

干预措施: 3-dimensional conformal radiation therapy (Radiation)

结局指标

主要结局

Local tumor control rate at 2 years

时间窗: 2 years

Overall tumor control rate will be assessed at 6 years

次要结局

  • Toxicity(6 years)
  • Disease recurrence rates(6 years)
  • Progression-free survival(6 years)
  • Overall survival(6 years)
  • Quality of life(6 years)
  • Changes in pulmonary function(6 years)

研究者

申办方类型
Network
责任方
Sponsor

研究点 (19)

Loading locations...

相似试验